Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor
Author:
Affiliation:
1. Department of Dermatology; University of Rochester Medical Center; Rochester NY USA
2. Department of Pathology; University of Rochester Medical Center; Rochester NY USA
Publisher
Wiley
Subject
Infectious Diseases,Dermatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.14143/fullpdf
Reference7 articles.
1. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1;Naidoo;Cancer Immunol Res,2016
2. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions;Jour;J Cutan Pathol,2016
3. Development of bullous pemphigoid during nivolumab therapy;Damsky;JAAD Case Rep,2016
4. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies;Hwang;Melanoma Res,2016
5. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma;Parakh;Australas J Dermatol,2016
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies;Cancers;2023-06-09
2. Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations;Frontiers in Immunology;2023-01-26
3. Immune checkpoint inhibitor-induced cutaneous toxicities: they are not just random;British Journal of Dermatology;2022-12-01
4. A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors;Cancers;2022-11-05
5. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer;JAMA Dermatology;2022-08-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3